Refine your search

Search Results within category "Lung Disease & Asthma"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Lung Disease & Asthma"


10 Study Matches

A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with idiopathic pulmonary fibrosis

This study will evaluate the effectiveness and safety of study drug PRM-151 compared with placebo in patients with idiopathic pulmonary fibrosis
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04552899
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults 40
•85 years of age
Diagnosis of Idiopathic Pulmonary Fibrosis
Exclusion Criteria:
Taking both nintedanib and pirfenidone
Receiving prednisone >10mg daily
Using more than 4 liters of oxygen/min
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For VIOLET

Site For VIOLET
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency
Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Infectious Diseases & Immune System, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Effects of antibiotic use on fecal microbiome and resistome

This study will investigate the changes in the human fecal microbiomes and resistomes in response to antibiotic treatment.
Jasna Kovac at jzk303@psu.edu or 814-699-1680
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
over age 18
English speaking/reading
Books a medical appointment for upper respiratory tract infection
Exclusion Criteria:
Patient took antibiotics in the past week
Patient participated in STUDY00012891 previously
Reason for medical visit is not upper respiratory tract infection
Patient is pregnant
Patient has a medical history that includes diagnosis of any intestinal related disease
Infectious Diseases & Immune System, Lung Disease & Asthma
  Email this study information to me
  Contact the study team

Evaluating the Cough Reflex in Fibrotic and Healthy Lungs

Determining cough threshold in patients with fibrotic lung disease and in healthy controls by stimulating cough.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
40 years of age or older
Patient Group: Fibrotic lung disease with chronic cough symptoms or Idiopathic cough syndrome
Healthy Control Group: no cough (either chronic or acute)
Exclusion Criteria:
Recent history of smoking (former smokers must be tobacco-free for at least 1 year)
History of (other) lung diseases
History of uncontrolled gastroesophageal reflux disease (GERD)
Use of exclusionary medications (i.e. steroids, ACE inhibitors, narcotics, cough suppressants)
History of uncontrolled post nasal drip
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

PSCI 21-064: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

A study designed to evaluate the efficacy and safety of BGB-A1217 + tislelizumab compared with that of pembrolizumab in patients with PD-L1-selected NSCLC who have locally advanced or recurrent disease that is unresectable or not amenable to radiotherapy, with or without chemoradiotherapy, or previously untreated metastatic disease, and whose tumors do not harbor EGFR-sensitizing mutations or ALK translocations. The efficacy and safety of tislelizumab alone will be explored in a small cohort of the same patient population.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04746924
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
No prior systemic treatment for metastatic NSCLC.
Age ≥ 18 years on the day of signing the informed consent form
Histologically or cytologically documented locally advanced or recurrent NSCLC that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic nonsquamous or squamous NSCLC.
ECOG Performance Status ≤ 1.
At least 1 measurable lesion as defined per RECIST v1.1.
Exclusion Criteria:
Known sensitizing mutation in the EGFR gene or an ALK fusion oncogene.
Active autoimmune diseases or history of autoimmune diseases that may relapse.
Active leptomeningeal disease or uncontrolled, untreated brain metastasis
Patients with active hepatitis C.
Known history of HIV infection.
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A 52-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype

Placebo-controlled efficacy and safety study of GSK3511294 in participants with severe asthma with an eosinophilic phenotype
Hunter Smith at hsmith16@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04718103
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Have, or a high likelihood of having eosinophilic asthma
Have at least 2 asthma attacks requiring steroids in the past 12 months
Take daily inhaled corticosteroids
Exclusion Criteria:
Women of childbearing potential must be on contraception
Participants who have received mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab (Fasenra) within the last 12 months
Participants who have received omalizumab (Xolair) or dupilumab (Dupixent) within last 130 days prior
Current smoker or history of smoking
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Recruitment for Nicotine and Tobacco Related Research at Penn State Hershey

The purpose of this project is to screen potential participants for multiple research studies being conducted by tobacco researchers at Penn State Hershey. Since there are multiple IRB approved studies enrolling at Penn State Hershey with similar but not identical inclusion/exclusion criteria, it is more efficient for the researchers and participants to have one phone number to call initially for basic screening. After completing this, the participant can be redirected for more specific screening if they are found to be potentially eligible for one of the studies.
Candace Bordner at cbordner@phs.psu.edu or 844-207-4594
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 21 or older
Current tobacco user
Exclusion Criteria:
Age less than 21
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 3 locations

Study Locations

Hide all locations
Location
Harrisburg, PA
Hershey, PA
York, PA

A Survey to Estimate the Socio-Economic Impact of the Novel Corona Virus (COVID-19) Pandemic

We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.
Pritish Mondal at pmondal@pennstatehealth.psu.edu or 717-897-0652
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General population
Adult
Exclusion Criteria:
Age below 18 years
Mentally impaired
Participants from Europe or European Union (EU)
Infectious Diseases & Immune System, Prevention, Lung Disease & Asthma
  Email this study information to me
  Contact the study team

A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF)

Assessment of the safety and tolerability of PLN-74809 following daily administration for up to 28 days in patients with idiopathic pulmonary fibrosis
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT04396756
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 50 years or older
Idiopathic Pulmonary Fibrosis (IPF) diagnosis
Exclusion Criteria:
Receiving non-approved agents to treat IPF
Need for continuous oxygen supplementation >15 hours/day
Active lung or sinus infection
Active smoker
Hepatic impairment or end-stage liver disease
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.
Kristina Richwine at krichwine@pennstatehealth.psu.edu or 717-531-4506
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04718389
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults 18 years or older at the time of signing the informed consent.
Have a documented diagnosis of asthma for 2 or more years.
Receiving either mepolizumab or benralizumab for 12 or more months prior to screening.
A well-documented requirement for regular treatment with medium to high dose inhaled corticosteroid in the 12 months prior to Visit 1 with or without maintenance oral corticosteroid.
Current treatment with at least one additional controller medication, besides an inhaled corticosteroids.
Exclusion Criteria:
Concurrent respiratory disease
Eosinophilic diseases
Pregnancy
Current or former smokers with a smoking history of 10 or more years.
Active COVID-19 infection
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA